Sudden Antipsychotic Withdrawal—Not Low Dose—Leads to Relapse
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.
Antipsychotic Adherence Research Overlooks Key Information
Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.
New Study: The Clinical High Risk for Psychosis (CHR-P) Model Is Flawed
The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.
Barriers to Shared Decision Making in the Prescription of Antipsychotics
Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.
Anticholinergic Medications Linked to Cognitive Impairment in Schizophrenia
Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.
Keys to Successful Discontinuation of Antipsychotic Medication
Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.
The BBC, Harrow, and a Public Left in the Dark
The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.
Recovery Rate Six Times Higher For Those Who Stop Antipsychotics Within Two Years
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.
A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.
Anticholinergic Drugs Increase Risk of Cognitive Decline
A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.
Antipsychotic Augmentation Increases Risk of Death
A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.
Greater Exposure to Antipsychotics Associated with Worse Long-Term Outcomes
A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.
Very Slow Taper Best for Antipsychotic Discontinuation
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
An FDA Whistleblower’s Documents: Commerce, Corruption, and Death
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
Antipsychotics Associated with Severe COVID-19 and Fatal Outcomes
A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.
For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
Do Antipsychotics Protect Against Early Death? A Review of the Evidence
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
Antipsychotic Trials Show Increasing Placebo Response and Declining Drug Response
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
Does Longer Duration of Untreated Psychosis Cause Worse Outcomes?
New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.
Largest Survey of Antipsychotic Experiences Reveals Negative Results
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
Review Explores First-Person Experiences of People Taking Antipsychotics
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
The Charade of New Drug Approvals for Schizophrenia
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
Relapse in Antipsychotic Drug Trials is Poorly Defined
There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.
